Table 1.
Author | Year | Data collection | Country | Age (years), median (IQR) OR mean (SD) | Gender, N (%) | NIHSS score at baseline, median (IQR) OR mean (SD) | Population (N) | Preoperative D-dimer, median (IQR) OR mean (SD) | EVT | Outcome of interest | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | Technique | Successful reperfusion | Favorable outcome | ||||||||||||
Definition | N | Definition | N | ||||||||||||
Aoki et al. 11 | 2020 | R | Japan | sMR: 82 (76–86); nsMR: 77 (71–83) | M = 72 (56.69) | sMR: 18 (13–24); nsMR: 19 (12–24) | 127 | sMR: 2.0 (1.1–3.4); nsMR: 1.6 (0.9–3.3) | 127 | Aspiration & Stent | TICI 3 | 53 | mRS 0–2 | 32 | Functional outcome |
Baek et al. 12 | 2023 | R | Republic of Korea | 71.3 (±12.9) | M = 113 (52.6) | 14.0 (9.0–19.0) | 215 | 757.0 (392.0–2562.5) ng/mL | 215 | Aspiration & Stent | mTICI ≥ 2b-3 | 203; FPE (mTICI 2c-3): 71 | mRS 0–2 | 87 | Successful reperfusion, FPE, and functional outcome |
Han et al. 13 | 2023 | R | China | 67.08 ± 11.67 | F = 87 (36) | 14 (11, 19) | 245 | 1.28 (0.7, 2.61) mg/L | 245 | Aspiration | - | - | mRS 0–2 | 122 | Deep venous thrombosis |
Hisamitsu et al. 14 | 2022 | R | Japan | 74.75 (±11.11) | M = 43 (49.4) | 15.51 (±5.95) | 87 | Favorable outcome: 1.74 (2.02); Unfavorable: 3.33 (3.16) µg/mL | 87 | Aspiration & Stent | mTICI ≥ 2b-3 | 80 | mRS 0–2 | 47 | Functional outcome |
Lee et al. 15 | 2021 | R | Republic of Korea | 68.46 ± 13.2 | M = 178 (52.2) | CRS: 18 (11–23); Control: 15 (8–19) | 341 | Favorable outcome: 10.7 (6.66–17.71); Unfavorable: 16.95 (14.55–26.60) | 341 | Aspiration & Stent | mTICI ≥ 2b-3 | 295 | mRS 0–2 | CRS: 11/34 | Functional outcome |
Li W. et al. 18 | 2020 | R | China | Reocclusion: 57.3 (±10.3); Non-reocclusion: 63.6 (±12.4) | M = 464 (75.57) | Occlusion: 15 (12–20); Non-reocclusion: 16 (12–23) | 614 | Reocclusion: 2 (0.8–4.7); Non-reocclusion: 0.8 (0.4–1.9) mmol/L | 614 | Stent | mTICI ≥ 2b-3 | - | mRS 0–2 | 230 | Re-occlusion rate |
Li J. et al. 16 | 2023 | R | China | 63.6 ± 12.6 | F = 104 (30.3) | 15.2 ± 4.5 | 343 | 1.3 (0.7–3.1) | 343 | Aspiration & Stent | mTICI ≥ 2b-3 | 259 | mRS <2 | 162 | Functional outcome |
Li L. et al. 17 | 2023 | R | China | Validation = favorable: 67 (59–71); unfavorable: 66 (59–70); Test = favorable: 54.5 (32–71.5); unfavorable: 61 (55.5–76) | M = 64 | Validation = favorable: 12 (9–15); unfavorable: 15 (13–18); Test = favorable: 14 (10.25–15.75); unfavorable: 13 (11–15) | 102 | Validation = favorable: 0.96 (0.59–2.24); unfavorable: 2.60 (0.92–190); Test = favorable: 1.00 (0.75–2.52); unfavorable: 0.59 (0.55–7.54) | 102 | NR | mTICI ≥ 2b-3 | 93 | mRS 0–2 | 46 | Functional outcome |
Mitsuhashi et al. 19 | 2023 | R | Japan | 85 (83–87) | F = 27 (61.02) | 24 (18–27) | 59 | Favorable: 1.25 (1.2–4.05); Unfavorable: 2 (0.875–1.8) µg/mL | 59 | Aspiration & Stent | mTICI ≥ 2b-3 | 44 | mRS 0–3 | 28 | Functional outcome |
Ohbuchi et al. 20 | 2022 | R | Japan | 76 ± 12 | F = 49 (40) | 18 ± 8 | 121 | 4.4 ± 6.6 µg/mL | 121 | Aspiration & Stent | mTICI ≥ 2b-3 | 88 | mRS 0–3 | 39 | Functional outcome and successful reperfusion |
Pan et al. 21 | 2022 | P | South Korea | 65.59 | M = 36 (52.9) | 15 (10–20) | 68 | 16.07 μg/mL | 36 | Aspiration & Stent | mTICI ≥ 2b-3 | 20 | mRS 0–2 | 18 | Functional outcome and successful reperfusion |
Qiu et al. 22 | 2022 | R | China | 69.7 ± 12.7 | M = 207 (52.4) | 16 (12–21) | 395 | 0.87 (0.42–1.83) mg/L | 395 | Aspiration & Stent | mTICI ≥ 2b-3 | 328 | - | - | sICH |
Song et al. 23 | 2020 | R | Republic of Korea | FPE: 69.6 (13.5); non-FPE: 68.0 (13.9) | M = 133 (55.88) | FPE: 10 (3–17); non-FPE: 9 (2–18) | 238 | FPE: 4 (3.86); non-FPE: 4.01 (3.75) mg/L | 238 | Stent | mTICI ≥ 2b-3 | 228 | mRS 0–2 | 141 | FPE |
Xie and Tang 24 | 2023 | R | China | 69.5 ± 12.9 | M = 163 (52.1) | 15 (12–21) | 313 | 0.85 (0.40–1.76) mg/L | 313 | Aspiration & Stent | mTICI ≥ 2b-3 | 254 | mRS 0–2 | 111 | FPE |
R: retrospective; P: prospective; M: male; F: female; sMR and nsMR: significant and non-significant mitral regurge; CRS: cancer-related stroke; FPE: first-pass effect; NR: not reported; mTICI: modified thrombolysis in cerebral infarction; sICH; symptomatic intracranial hemorrhage; mRS: modified Rankin scale; NIHSS: National Institute of Health Stroke Scale; DVT: deep venous thrombosis.